Group 1 - The A-share biopharmaceutical sector experienced a significant afternoon rally, with notable increases in stock prices [1] - Zhifei Biological surged over 14%, while Watson Bio rose more than 12% [1] - Other companies such as Kangtai Biological, Sanyuan Gene, Bohui Innovation, Baike Biological, and Zhixiang Jintai also saw gains [1]

Core Viewpoint - The article discusses the significant developments in the field of shingles vaccines in China, highlighting the price reduction initiatives and the emergence of domestic vaccine production, particularly by Changchun Baike Biotechnology Co., Ltd. [5][6] Group 1: Vaccine Market Dynamics - The shingles vaccine market in China is experiencing a price reduction trend, driven by the "Healthy China" strategy, which aims to enhance public health through affordable vaccination programs [5]. - There are currently two approved shingles vaccines in China: one imported and one domestically produced by a company based in Changchun, Jilin [5][6]. Group 2: Company Innovations and Developments - Changchun Baike Biotechnology has launched the first domestically developed live attenuated shingles vaccine for individuals aged 40 and above, breaking the monopoly of imported vaccines in the market [6]. - The parent company, Changchun High-tech Industry (Group) Co., Ltd., has shifted its focus towards innovation in the biopharmaceutical sector, investing over 8.5 billion yuan in research and development [6][8]. Group 3: Regional Industry Growth - The biopharmaceutical industry in Changchun is supported by a robust infrastructure and educational resources, including institutions like the Chinese Academy of Sciences and several key universities [8]. - The biopharmaceutical and life health industry in Changchun is projected to achieve a production value of 110 billion yuan in 2024, reflecting a year-on-year growth of 12.5% [8][11]. Group 4: Future Prospects - The "Yongchun Biopharmaceutical City" is under construction, with 33 projects and a total investment of 15.2 billion yuan, expected to generate a production value of 60 billion yuan by 2035 [11]. - The local government has introduced a three-year action plan to further develop the biopharmaceutical and life health industry as a new growth engine for the city's economy [11][13].

1、长春百克生物科技股份公司（以下简称"公司"）近日收到国家药品监督 管理局下发的流感病毒裂解疫苗（BK-01 佐剂）的《药物临床试验批准通知书》。 证券代码：688276 证券简称：百克生物 公告编号：2025-024 长春百克生物科技股份公司 关于自愿披露流感病毒裂解疫苗（BK-01 佐剂） 临床试验申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2、本次获批临床试验的流感病毒裂解疫苗（BK-01 佐剂）后续临床试验的开 展具有一定的不确定性，能否最终实现商业目的也存在一定的不确定性。敬请广大 投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 一、《药物临床试验批准通知书》的主要信息 受理号：CXSL2500239 通知书编号：2025LP01603 药品名称：流感病毒裂解疫苗（BK-01 佐剂） 结论：同意开展预防疫苗相关型别流感病毒引起的流行性感冒的临床试验。 批准日期：2025 年 6 月 19 日 二、流感病毒裂解疫苗（BK-01 佐剂）的简介 流感是由流感病毒引起 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for a clinical trial of its influenza virus split vaccine (BK-01 adjuvant), targeting individuals aged 60 and above to prevent influenza caused by the virus [1] Group 1 - The vaccine is designed specifically for the elderly population, which is at higher risk for influenza complications [1] - The vaccine utilizes a split virus technology route combined with a self-developed adjuvant to enhance immunogenicity [1] - Successful development of this vaccine will enrich the company's influenza vaccine research pipeline and provide new vaccination options for the elderly [1]

证券代码：688276 证券简称：百克生物 公告编号：2025-023 长春百克生物科技股份公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/17 | 2025/6/18 | 2025/6/18 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1. 发放年度：2024年年度 2. 分派对象： 3. 分配方案： 本次利润分配以方案实施前的公司总股本413,657,598股为基数，每股派发现 金红利0.169元（含税），共计派发现金红利69,908,134.06元（含税）。 三、 相关日期 1 是否涉及差异化分红送转：否 每 ...

Core Viewpoint - Changchun Baike Biotechnology Co., Ltd. has announced a cash dividend distribution of 0.169 CNY per share, totaling approximately 69.91 million CNY, approved at the 2024 annual shareholders' meeting on May 13, 2025 [1][2]. Dividend Distribution Plan - The total share capital before the distribution is 413,657,598 shares, with a cash dividend of 0.169 CNY per share, amounting to a total distribution of 69,908,134.06 CNY (including tax) [1]. - The cash dividend will be distributed to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, after the market closes on the registration date [1]. Relevant Dates - The key dates for the dividend distribution are as follows: - Registration Date - Ex-Dividend Date - Cash Dividend Payment Date [1]. Taxation Policies - For individual shareholders holding unrestricted circulating shares, dividends are subject to different tax treatments based on the holding period: - Over 1 year: Tax-exempt on dividend income, actual cash dividend per share is 0.169 CNY [2]. - 1 year or less: No withholding tax at the time of distribution; tax will be calculated upon sale of shares [2]. - For shares held less than 1 month, the effective tax burden is 20% [2]. Special Cases for Restricted Shares - For shareholders holding restricted shares, dividends received after the lifting of restrictions will be taxed similarly to unrestricted shares, while dividends received before the lifting will be taxed at a reduced rate [3]. - Non-resident enterprises holding restricted shares will be taxed at a rate of 10%, with a net dividend of 0.1521 CNY per share [4]. QFII and Hong Kong Investors - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax on dividends, resulting in a net dividend of 0.1521 CNY per share [4]. - Investors from Hong Kong holding shares through the Shanghai-Hong Kong Stock Connect will also face a 10% withholding tax, with the same net dividend amount [5]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the Board Office at 0431-81871518 [6].

一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东会审议通过。 证券代码：688276 证券简称：百克生物 公告编号：2025-023 长春百克生物科技股份公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/17 | 2025/6/18 | 2025/6/18 | 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0.169元 相关日期 1. 发放年度：2024年年度 2. 分派对象： 3. 分配方案： 本次利润分配以方案实施前的公司总股本413,657,598股为基数，每股派发现 金红利0.169元（含税），共计派发现金红利69,9 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-022 长春百克生物科技股份公司 关于自愿披露重组带状疱疹疫苗（CHO 细胞） 临床试验申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、长春百克生物科技股份公司（以下简称"公司"）近日收到国家药品监督 管理局下发的重组带状疱疹疫苗（CHO 细胞）的《药物临床试验批准通知书》。 二、重组带状疱疹疫苗（CHO 细胞）的简介 带状疱疹是由潜伏在机体内的水痘-带状疱疹病毒（VZV）重新被激活引起的 急性感染性皮肤病，该病毒具有嗜神经性，初次感染后可长期潜伏在脊髓神经后根 或脑神经节的神经元内，在某些诱因的刺激下，潜伏的病毒沿感觉神经移动到达支 配的皮肤，迅速增殖复制使受感染细胞发炎、坏死造成神经痛，并沿着神经纤维通 路到达皮肤表面，出现呈带状分布的红斑及簇集水疱。带状疱疹多发于老年人和免 2、本次获批临床试验的重组带状疱疹疫苗（CHO 细胞）后续临床试验的开展 具有一定的不确定性，能否最终实现商业目的也存在一定的不确定性。敬请广 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-021 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，长春百克生物科技股份公司（以下简称 "公司"）将参加由吉林省证券业协会、深圳市全景网络有限公司共同举办的 "2025 年吉林辖区上市公司投资者网上集体接待日活动"，现将有关事项公告如 下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2025 年 5 月 27 日（周二）15:00-16:30。 届时公司董事、总经理姜春来先生、独立董事吴安平先生、财务总监孟昭峰 先生、董事会秘书张喆先生将在线就公司 2024 年度业绩、公司治理、发展战略、 经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 长春百克生物科技股份公司董事会 2025 年 5 月 20 日 长春百克生物科技股份公司 关于 ...

Core Viewpoint - The price reduction trend for self-paid vaccines has reached the shingles vaccine, with significant price cuts observed in various regions of China, aiming to increase vaccination rates among the population [1][2]. Price Reduction and Promotional Activities - Since March 2023, the price of shingles vaccines in regions like Inner Mongolia, Shandong, Henan, and Chongqing has been halved compared to last year, with some areas offering "buy one get one free" promotions [2]. - The "2025 Domestic Shingles Vaccine Benefit Project" offers a half-price vaccination for residents over 40, reducing the original price from 1389 yuan to 704.5 yuan, saving 684.5 yuan [3]. - A promotional activity allows individuals to complete the first dose between May and August 2025 and the second dose by December 31, 2025, reducing the total cost from 3260 yuan to 1652 yuan [4][6]. Market Competition and Pricing Discrepancies - The two available shingles vaccines in China, one imported from GlaxoSmithKline and one domestic from Baike Biological, are experiencing inconsistent price reductions, leading to regional competition [7]. - In some areas, only the imported vaccine has seen a price drop, while the domestic vaccine remains at its original price [7]. Vaccination Rates and Challenges - The vaccination rate for shingles among adults aged 40 and older in China is extremely low, at only 0.79% as of September 2024, compared to 41.1% in the U.S. for those aged 60 and above [12][13]. - High self-paid prices are a significant barrier to increasing vaccination rates, with the cost of the imported vaccine previously equating to nearly a month's pension for retirees in cities like Guangzhou [14]. - There is a lack of awareness and understanding of shingles and its vaccine among the elderly, further limiting vaccination uptake [12][15]. Inventory and Sales Performance - Baike Biological has faced challenges with unsold inventory, leading to a significant increase in accounts receivable and inventory levels, indicating poor sales performance [8][9]. - GlaxoSmithKline's vaccine has seen a decline in expected sales, with procurement agreements being extended to 2029 due to underperformance [10][11]. Healthcare Infrastructure and Service Limitations - The current healthcare infrastructure for adult vaccination is inadequate, with insufficient resources and a lack of clear guidelines for adult immunization services [16]. - Many vaccination centers are not equipped to handle adult vaccinations, leading to a conservative approach in recommending vaccines to the elderly [16].